Research Article
Potential Canonical Wnt Pathway Activation in High-Grade Astrocytomas
Table 2
Clinicopathological characteristics of patients included in TMA analysis.
| Histological diagnosis | | Patients | | | (%) | |
| Glioblastoma | WHO IV | 221 (78.1) | | Anaplastic astrocytoma | WHO III | 17 (6.0) | | Diffuse astrocytoma | WHO II | 45 (15.9) | |
| Age | | mean () ± SD | |
| Glioblastoma | WHO IV | 53.8 ± 12.8 | | Anaplastic astrocytoma | WHO III | 36.1 ± 14.2 | | Diffuse astrocytoma | WHO II | 33.6 ± 18.7 | |
| Gender | | M : F | |
| Glioblastoma | WHO IV | 133 : 88 | | Anaplastic astrocytoma | WHO III | 11 : 6 | | Diffuse astrocytoma | WHO II | 30 : 15 | |
| Extent of resection | | Total | Subtotal/biopsy | | | = (%) | = (%) |
| Glioblastoma | WHO IV | 151 (68.3) | 70 (31.7) | Anaplastic astrocytoma | WHO III | 11 (64.7) | 6 (35.3) | Diffuse astrocytoma | WHO II | 33 (73.3) | 12 (26.7) |
| Adjuvant treatment† | | Radiotherapy | Chemotherapy | | | = (%) | = (%) |
| Glioblastoma | WHO IV | 186 (84.2) | 87 (39.4) | Anaplastic astrocytoma | WHO III | 16 (94.1) | 1 (5.9) | Diffuse astrocytoma | WHO II | 14 (31.1) | 3 (6.7) |
|
|
†Therapy at primary tumour diagnosis.
|